



To all concerned stakeholders,

Asteria Corporation  
(TSE Prime Market: 3853)  
Contact: Yasuhisa Saito, CFO  
(Phone: +81-3-5718-1655)

**Notice Regarding Recording of Extraordinary Losses and Differences Between Financial Results for Fiscal Year Ended March 2023 and the Previous Year's Results (on a Non-Consolidated Basis)**

Tokyo -- May 15, 2023 -- Asteria Corporation hereby announces that it has recorded extraordinary losses in its non-consolidated financial results for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023; hereinafter FY2022) in a meeting of the Board of Directors held today. Furthermore, Asteria announces the differences between the non-consolidated financial results for FY2022 and those for FY2021. as follows:

**1. Details**

As revenues from wholly-owned subsidiary This Place Limited grew slower than originally expected, Asteria examined the business environment surrounding the company as well as its financial position and business performance, and reevaluated the shares. This led to the recording of losses on valuation of stocks of subsidiaries and affiliates of about 1.022 billion yen as extraordinary losses in its non-consolidated financial results for FY2022.

The losses on valuation of stocks of subsidiaries and affiliates will have no impact on the consolidated financial statements as it will be offset and eliminated in the consolidated results.

**2. Differences Between the Non-Consolidated Financial Results for FY2022 and those for FY2021**

	Revenue	Operating profit	Ordinary profit	Net profit attributable to owners of the parent	Earnings per share
	Million Yen	Million Yen	Million Yen	Million Yen	Yen
FY2021 Results (A)	2,562	56	237	215	13.02
FY2022 Results (B)	2,859	132	326	(678)	(40.35)
Change (B -A)	297	76	89	(893)	—
Change (%)	11.6%	134.8%	37.7%	—	—

**3. Reason for the Differences**

The non-consolidated revenues exceeded those for the previous fiscal year as a result of growth in the Software Business whose core product is "ASTERIA Warp".

The non-consolidated operating profit and ordinary profit rose with revenue growth, despite an increase in selling, general, and administrative expenses as a result of personnel expansion and marketing campaigns conducted in line with the Med-Term Management Plan "STAR," which began in FY2021. However, net profit decreased due to losses on valuation of stocks of subsidiaries and affiliates as described in "1. Details" .

\*For the consolidated financial performance for FY2022, please refer to the "Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (IFRS)" disclosed today.